40.91
+1.55(+3.94%)
Currency In USD
Address
445 Marine View Avenue
Solana Beach, CA 92014
United States of America
Phone
(858) 925-7000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
March 22, 2024
| Name | Title | Pay | Year Born |
| Mr. Evert B. Schimmelpennink | President, Chief Executive Officer, Secretary & Director | 1.07M | 1972 |
| Mr. James W. McCollum | Co-Founder & Director | 31,209 | 1955 |
| Mr. Shawn Olsson | Chief Commercial Officer | 532,133 | 1983 |
| Mr. Daniel R. Chevallard CPA | Chief Financial Officer | 680,368 | 1980 |
| Mr. Marc G. Odrich M.D. | Chief Medical Officer | 732,250 | 1959 |
| Kris Gambelin | Senior Vice President of Regulatory & Clincal Operations | 0 | N/A |
| Ms. Breianna Bowen | Vice President of Human Resources | 0 | N/A |
| Mr. Domenick Porfidia | Vice President of Sales | 0 | N/A |
| Mr. David Choromanski | Vice President of Marketing | 0 | N/A |
| Ms. Melissa Rosness | Senior Vice President of Manufacturing Operations | 0 | N/A |
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.